Skip to content

Qing Re Xiao Yan Wan for upper respiratory tract infection (heat-toxin invading lung syndrome): a multicenter, randomized, placebo-controlled trial

Qing Re Xiao Yan Wan for upper respiratory tract infection (heat-toxin invading lung syndrome): a multicenter, randomized, placebo-controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-10001105
Enrollment
Unknown
Registered
2010-11-18
Start date
2010-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

upper respiratory tract infection

Interventions

1:Qing Fei Xiao Yan Wan
2:Placebo

Sponsors

Dong Zhi Men Hospital, Beijing University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with upper respiratory tract infection based on "National Guideline for the Diagnosis and Treatment of Influenza (draft)" released by the Branch of Respiratory Diseases of Chinese Medical Association in 2002; 2. With heat-toxin invading lung syndrome based on TCM theory; 3. Onset of the disease within 24 hours; 4. Temperature >=37.5 degree C; 5. Aged between 18 and 65 years old; 6. Sign the informed consent documents.

Exclusion criteria

Exclusion criteria: 1. Comorbidities with lung infection, lung tuberculosis, branchial carcinoma, bronchial pneumonia and other lung diseases; 2. Comorbidities with primary diseases of cardiovascular system, liver, kidney and hematological system; or with psychic disorders; 3. Allergic constitution; 4. Serum transaminase higher than 1.5 times of normal range; 5. Participate in other medicine clinical trials; 6. Pregnant or breast-feeding females; 7. Use other western or Chinese medicine for the disease within 24 hours of the trial; 8. With alcoholic or drug abuse history; or other conditions that are not suitable for the trial, such as frequent change of work place that might influence the follow-ups.

Design outcomes

Primary

MeasureTime frame
3-day cure rate;

Secondary

MeasureTime frame
Efficacy for diseases;Time needed for defervescence, improvements and clearance;Efficacy for TCM syndromes;Percentage of remission of fever;Virus nucleic acid test;Changes of symptoms and signs;

Countries

China

Contacts

Public ContactLiangduo Jiang
liangduojiang@163.com+86 13901365516

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026